Concepedia

Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 Study

Hirotoshi Iihara, Mototsugu Shimokawa, Hiroko Bando, Yoshimi Niwa, Yutaka Mizuno, Yoshihiro Kawaguchi, Mika Kitahora, Akari Murakami, Masaaki Kawai, Kazushige Ishida,

Journal of Cancer · 2023 · 12 citations · 15 references

DOIFull text

Open access

Concepts

Abstract

Patients receiving trastuzumab deruxtecan require triple therapy, including mandatory NK1RA administration.

References

15

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi, William Jacot, Toshinari Yamashita et al. · New England Journal of Medicine · 2022 · 2.5K citations · Full text

, , +17

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi, Cristina Saura, Toshinari Yamashita et al. · New England Journal of Medicine · 2019 · 2K citations · Full text

, , +17

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa et al. · New England Journal of Medicine · 2020 · 1.3K citations · Full text

, , +17

Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer

Bob T. Li, Egbert F. Smit, Yasushi Goto et al. · New England Journal of Medicine · 2021 · 980 citations · Full text

, , +16

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

Fausto Roila, Alex Molassiotis, Jørn Herrstedt et al. · Annals of Oncology · 2016 · 580 citations · Full text

, , +14